Involvement of α-klotho, fibroblast growth factor-, vitamin-D- and calcium-sensing receptor in 53 patients with primary hyperparathyroidism

Endocrine

Volumn 44, Issue 1, 2013, Pages 255-263

  Latus, Joerg ^a   Lehmann, Renate ^a   Roesel, Meike ^a   Fritz, Peter ^a   Braun, Niko ^a   Ulmer, Christoph ^a   Steurer, Wolfgang ^a   Biegger, Dagmar ^b   Ott, German ^a   Dippon, Juergen ^c   Alscher, M Dominik ^a   Kimmel, Martin ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

Author keywords

CaSR; FGFR; Klotho; Primary hyperparathyroidism; VDR

Indexed keywords

ALPHA KLOTHO PROTEIN; CALCIUM; CALCIUM SENSING RECEPTOR; FIBROBLAST GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; KLOTHO PROTEIN; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADIPOCYTE; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL FEATURE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PARATHYROID GLAND; PARATHYROIDECTOMY; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, CALCITRIOL; RECEPTORS, CALCIUM-SENSING; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84881129478     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9881-6     Document Type: Article

References (31)

1. N.D. Perrier, Asymptomatic hyperparathyroidism: a medical misnomer? Surgery 137(2), 127-131 (2005). doi: 10.1016/j.surg.2004.06.037
2. E. Lundgren, E. Szabo, S. Ljunghall, R. Bergstrom, L. Holmberg, J. Rastad, Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism. BMJ 317(7162), 848-851 (1998)
3. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58-69 (2012). doi: 10.1007/s12020-011-9570-2
4. J.M. Ruda, Hollenbeak, CS., Stack BC. Jr.: A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngology-head and neck surgery. Otolaryngol. Head Neck Surg. 132(3), 359-372 (2005). doi: 10.1016/j.otohns.2004.10.005
5. D. Bartsch, C. Nies, C. Hasse, J. Willuhn, M. Rothmund, Clinical and surgical aspects of double adenoma in patients with primary hyperparathyroidism. Br. J. Surg. 82(7), 926-929 (1995)
6. L.H. Duntas, N. Stathatos, Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine 39(3), 199-204 (2011). doi: 10.1007/s12020-011-9452-7
7. B. Larian, S. Alavi, J. Roesler, A. Namazie, K. Blackwell, T.C. Calcaterra, M.B. Wang, The role of hyperplasia in multiple parathyroid adenomas. Head Neck 23(2), 134-139 (2001)
8. A. Stojadinovic, A. Hoos, A. Nissan, M.E. Dudas, C. Cordon-Cardo, A.R. Shaha, M.F. Brennan, B. Singh, R.A. Ghossein, Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum. Pathol. 34(1), 54-64 (2003). doi: 10.1053/hupa.2003.55
9. A. Gurrado, A. Marzullo, G. Lissidini, A. Lippolis, D. Rubini, G. Lastilla, M. Testini, Substernal oxyphil parathyroid adenoma producing PTHrP with hypercalcemia and normal PTH level. World J. Surg. Oncol. 6, 24 (2008). doi: 10.1186/1477-7819-6-24
10. J. Fleischer, C. Becker, D. Hamele-Bena, T.L. Breen, S.J. Silverberg, Oxyphil parathyroid adenoma: a malignant presentation of a benign disease. J. Clin. Endocrinol. Metab. 89(12), 5948-5951 (2004). doi: 10.1210/jc.2004-1597
11. E. Demiralay, G. Altaca, B. Demirhan, Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of PCNA and Ki-67 proliferation markers. Turk. Patoloji. Dergisi. 27(3), 215-220 (2011). doi: 10.5146/tjpath.2011.01078
12. S. Varshney, S.K. Bhadada, U. Nahar, V.N. Shah, A. Bhansali, A. Behera, Chief cell and clear cell parathyroid adenoma do not influence clinical and biochemical expression of the sporadic primary hyperparathyroidism. Endocrine (2012). doi: 10.1007/s12020-012-9810-0
13. D. Sudhaker Rao, Z.H. Han, E.R. Phillips, S. Palnitkar, A.M. Parfitt, Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin. Endocrinol. 53(3), 373-381 (2000)
14. T. Carling, J. Rastad, E. Szabo, G. Westin, G. Akerstrom, Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 85(5), 2000-2003 (2000)
15. S. Yano, T. Sugimoto, T. Tsukamoto, K. Chihara, A. Kobayashi, S. Kitazawa, S. Maeda, R. Kitazawa, Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur. J. Endocrinol. 148(4), 403-411 (2003)
16. I.Z. Ben-Dov, H. Galitzer, V. Lavi-Moshayoff, R. Goetz, M. Kuro-o, M. Mohammadi, R. Sirkis, T. Naveh-Many, J. Silver, The parathyroid is a target organ for FGF23 in rats. J. Clin. Investig. 117(12), 4003-4008 (2007). doi: 10.1172/JCI32409
17. T. Krajisnik, P. Bjorklund, R. Marsell, O. Ljunggren, G. Akerstrom, K.B. Jonsson, G. Westin, T.E. Larsson, Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 195(1), 125-131 (2007). doi: 10.1677/JOE-07-0267
18. H. Yamashita, T. Yamashita, M. Miyamoto, T. Shigematsu, J.J. Kazama, T. Shimada, Y. Yamazaki, S. Fukumoto, M. Fukagaw, S. Noguchi, Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 151(1), 55-60 (2004)
19. K. Kobayashi, Y. Imanishi, A. Miyauchi, N. Onoda, T. Kawata, H. Tahara, H. Goto, T. Miki, E. Ishimura, T. Sugimoto, T. Ishikawa, M. Inaba, Y. Nishizawa, Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur. J. Endocrinol. 154(1), 93-99 (2006). doi: 10.1530/eje.1.02053
20. P. Bjorklund, T. Krajisnik, G. Akerstrom, G. Westin, T.E. Larsson, Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 93(10), 4152-4157 (2008). doi: 10.1210/jc.2008-0564
21. N. Braun, M.D. Alscher, M. Kimmel, K. Amann, M. Buttner, Encapsulating peritoneal sclerosis - an overview. Nephrol. Ther. 7(3), 162-171 (2011). doi: 10.1016/j.nephro.2010.12.011
22. R.A. Wermers, S. Khosla, E.J. Atkinson, S.J. Achenbach, A.L. Oberg, C.S. Grant, L.J. Melton 3rd, Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J. Bone. Miner. Res. 21(1), 171-177 (2006). doi: 10.1359/JBMR.050910
23. A. Garcia-Martin, R. Reyes-Garcia, M. Munoz-Torres, Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42(3), 764-766 (2012). doi: 10.1007/s12020-012-9694-z
24. K. Nakajima, T. Okazaki, T. Okamoto, H. Kimura, K. Takano, K. Sato, Genes up- or down-regulated by high calcium medium in parathyroid tissue explants from patients with primary hyperparathyroidism. Endocr. J. 57(2), 153-159 (2010)
25. I. Urakawa, Y. Yamazaki, T. Shimada, K. Iijima, H. Hasegawa, K. Okawa, T. Fujita, S. Fukumoto, T. Yamashita, Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444(7120), 770-774 (2006). doi: 10.1038/nature05315
26. T. Kawata, Y. Imanishi, K. Kobayashi, T. Miki, A. Arnold, M. Inaba, Y. Nishizawa, Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 18(10), 2683-2688 (2007). doi: 10.1681/ASN.2006070783
27. A. Imura, Y. Tsuji, M. Murata, R. Maeda, K. Kubota, A. Iwano, C. Obuse, K. Togashi, M. Tominaga, N. Kita, K. Tomiyama, J. Iijima, Y. Nabeshima, M. Fujioka, R. Asato, S. Tanaka, K. Kojima, J. Ito, K. Nozaki, N. Hashimoto, T. Ito, T. Nishio, T. Uchiyama, T. Fujimori, Y. Nabeshima, Alpha-klotho as a regulator of calcium homeostasis. Science 316(5831), 1615-1618 (2007). doi: 10.1126/science.1135901
28. C. Kumata, M. Mizobuchi, H. Ogata, F. Koiwa, A. Nakazawa, F. Kondo, Y. Kadokura, E. Kinugasa, T. Akizawa, Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am. J. Nephrol. 31(3), 230-238 (2010). doi: 10.1159/000274483
29. H. Komaba, S. Goto, H. Fujii, Y. Hamada, A. Kobayashi, K. Shibuya, Y. Tominaga, N. Otsuki, K. Nibu, K. Nakagawa, N. Tsugawa, T. Okano, R. Kitazawa, M. Fukagawa, T. Kita, Depressed expression of klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77(3), 232-238 (2010). doi: 10.1038/ki.2009.414
30. F. Farnebo, U. Enberg, L. Grimelius, M. Backdahl, M. Schalling, C. Larsson, L.O. Farnebo, Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 82(10), 3481-3486 (1997)
31. +-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81(4), 1598-1606 (1996)